These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6126136)

  • 21. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
    Rosenthal J; Jaeger H; Specker M
    Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of triamterene and its metabolite in man.
    Hasegawa J; Lin ET; Williams RL; Sörgel F; Benet LZ
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):507-23. PubMed ID: 7166735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients.
    Deneke J; Luckow V; Guserle R; Pässler HH
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):418-24. PubMed ID: 9726694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 27. New insights into the pharmacokinetics of spironolactone.
    Overdiek HW; Hermens WA; Merkus FW
    Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of the cardiac effects of triamterene and its phase II metabolite p-hydroxytriamterene sulphuric acid ester (author's transl].
    Greeff K; Schuhmacher P
    Arzneimittelforschung; 1979; 29(4):705-6. PubMed ID: 582773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Animal experimental and human pharmacologic studies with phase-II metabolites of triamterene].
    Völger KD
    Arzneimittelforschung; 1991 May; 41(5):499-506. PubMed ID: 1898420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
    Jeunesse E; Woehrle F; Schneider M; Lefebvre HP
    J Vet Cardiol; 2007 Nov; 9(2):63-8. PubMed ID: 18024236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Distribution volume and elimination of triamterene and its active metabolites in the rabbit (author's transl)].
    Knauf H; Mutschler E; Wais S; Wais U
    Arzneimittelforschung; 1978; 28(8):1414-6. PubMed ID: 582408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of a simple fluorometric method on absorption of canrenone.
    Radó JP; Szende L; Takó J; Nagy O; Kozma C
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspects on pharmacokinetics of some diuretics.
    Beermann B
    Acta Pharmacol Toxicol (Copenh); 1984; 54 Suppl 1():17-29. PubMed ID: 6369882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].
    d'Athis P; Richard MO; de Lauture D; Rey E; Bouvier d'Yvoire M; Clement E; Olive G
    Therapie; 1981; 36(4):443-9. PubMed ID: 7292427
    [No Abstract]   [Full Text] [Related]  

  • 35. Age effect on perfluorooctanoate (PFOA) plasma concentration in post-weaning rats following oral gavage with ammonium perfluorooctanoate (APFO).
    Hinderliter PM; Han X; Kennedy GL; Butenhoff JL
    Toxicology; 2006 Aug; 225(2-3):195-203. PubMed ID: 16857306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
    Peck RW; Seaber EJ; Dixon RM; Layton GR; Weatherley BC; Jackson SH; Rolan PE; Posner J
    Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Furosemide--pharmacokinetics in geriatric patients with multimorbidity].
    Neubig E; Mühlberg W; Platt D
    Z Gerontol; 1984; 17(5):251-60. PubMed ID: 6523981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relative bioavailability of a new spironolactone preparation (author's transl)].
    Erking W; Lücker PW; Stöcker KP; Wetzelsberger K
    Arzneimittelforschung; 1979; 29(8):1184-9. PubMed ID: 583021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly and young subjects.
    Kumagai Y; Yokota S; Isawa S; Murasaki M; Mukai H; Miyatake S
    Int J Clin Pharmacol Res; 1999; 19(1):1-8. PubMed ID: 10450537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.